REGiMMUNE Corporation is a private biopharmaceutical company that develops innovative solutions for immune disorders caused by nonspecific and excessive immune reactions. Using their proprietary technology platform, reVax, they induce regulatory T cells to target immune tolerance against disease-causing antigens. Their clinical-stage compound, RGI-2001, is being tested for Graft versus Host Disease, while a second product, RGI-3001, is in preclinical development for treating type 1 diabetes. REGiMMUNE aims to reduce side effects associated with conventional immunosuppressants and provide effective treatment for a range of immune diseases and disorders.